PROQR THERAPEUTICS EO-04 Net Assets
PROQR THERAPEUTICS EO-04 net assets. Based on the latest financial reports, PROQR THERAPEUTICS EO-04 (0PQ) has net assets worth €49.37 Million EUR (≈ $57.72 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€112.76 Million ≈ $131.82 Million USD) and total liabilities (€63.38 Million ≈ $74.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore PROQR THERAPEUTICS EO-04 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €49.37 Million |
| % of Total Assets | 43.79% |
| Annual Growth Rate | -18.74% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 67.18 |
Net Assets of PROQR THERAPEUTICS EO-04 (2021–2025)
Net assets of PROQR THERAPEUTICS EO-04 from 2021 to 2025. This chart illustrates how PROQR THERAPEUTICS EO-04's net assets have evolved over time, based on quarterly financial data. See PROQR THERAPEUTICS EO-04 (0PQ) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for PROQR THERAPEUTICS EO-04 (2021–2025)
The table below shows the annual net assets of PROQR THERAPEUTICS EO-04 from 2021 to 2025. For live market cap and overall valuation, see 0PQ market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €49.37 Million ≈ $57.72 Million |
-44.25% |
| 2024-12-31 | €88.56 Million ≈ $103.54 Million |
+113.96% |
| 2023-12-31 | €41.39 Million ≈ $48.39 Million |
-37.93% |
| 2022-12-31 | €66.68 Million ≈ $77.96 Million |
-41.11% |
| 2021-12-31 | €113.23 Million ≈ $132.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PROQR THERAPEUTICS EO-04's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14973600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
PROQR THERAPEUTICS EO-04 Net Assets Breakdown (December 2025)
PROQR THERAPEUTICS EO-04 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €516.88 Million | 1046.87% |
| Total Equity | €49.37 Million | 100.00% |
PROQR THERAPEUTICS EO-04 Competitors by Market Cap
The table below lists competitors of PROQR THERAPEUTICS EO-04 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Excelliance MOS
TWO:5299
|
$142.37 Million |
|
Protara Therapeutics Inc
NASDAQ:TARA
|
$142.42 Million |
|
Clarus Corp
NASDAQ:CLAR
|
$142.43 Million |
|
Ilex Medical
TA:ILX
|
$142.48 Million |
|
Corem Property Group AB (publ)
ST:CORE-D
|
$142.33 Million |
|
St.Shine Optical Co Ltd
TWO:1565
|
$142.32 Million |
|
Biomm S.A
SA:BIOM3
|
$142.31 Million |
|
Thong Guan Industries Bhd
KLSE:7034
|
$142.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PROQR THERAPEUTICS EO-04's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 88,560,000 to 49,374,000, a change of -39,186,000 (-44.2%).
- Net loss of 42,184,000 reduced equity.
- Other factors increased equity by 2,998,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-42.18 Million | -85.44% |
| Other Changes | €3.00 Million | +6.07% |
| Total Change | €- | -44.25% |
Book Value vs Market Value Analysis
This analysis compares PROQR THERAPEUTICS EO-04's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.77x to 2.63x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.60 | €1.23 | x |
| 2022-12-31 | €0.83 | €1.23 | x |
| 2023-12-31 | €0.51 | €1.23 | x |
| 2024-12-31 | €0.84 | €1.23 | x |
| 2025-12-31 | €0.47 | €1.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PROQR THERAPEUTICS EO-04 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -85.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -265.21%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 2.28x
- Recent ROE (-85.44%) is below the historical average (-66.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -53.36% | -4549.81% | 0.01x | 1.84x | €-72.12 Million |
| 2022 | -96.06% | -1792.54% | 0.02x | 2.55x | €-71.13 Million |
| 2023 | -67.94% | -431.67% | 0.05x | 3.33x | €-32.26 Million |
| 2024 | -31.35% | -146.86% | 0.11x | 1.90x | €-36.62 Million |
| 2025 | -85.44% | -265.21% | 0.14x | 2.28x | €-47.12 Million |
Industry Comparison
This section compares PROQR THERAPEUTICS EO-04's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,903,408
- Average return on equity (ROE) among peers: -58.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PROQR THERAPEUTICS EO-04 (0PQ) | €49.37 Million | -53.36% | 1.28x | $142.34 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more